Yamashita Soichiro, Fukuzawa Koji, Yoshida Akihiro, Itoh Mitsuaki, Imamura Kimitake, Fujiwara Ryudo, Suzuki Atsushi, Nakanishi Tomoyuki, Matsumoto Akinori, Kanda Gaku, Kiuchi Kunihiko, Shimane Akira, Okajima Katsunori, Tanaka Hidekazu, Hirata Ken-Ichi
Section of Arrhythmia, Division of Cardiovascular Medicine, Kobe University Graduate School of Medicine, 7-5-2, Kusunoki-cho, Chu-ou-ku, Kobe, Japan.
Section of Arrhythmia, Division of Cardiovascular Medicine, Kobe University Graduate School of Medicine, 7-5-2, Kusunoki-cho, Chu-ou-ku, Kobe, Japan ; Division of Cardiovascular Medicine, Kobe University Graduate School of Medicine, Kobe, Japan.
J Arrhythm. 2015 Aug;31(4):221-5. doi: 10.1016/j.joa.2014.12.008. Epub 2015 Feb 13.
We reviewed the effectiveness and safety of cardiac resynchronization therapy (CRT) for patients with New York Heart Association (NYHA) class IV non-ambulatory heart failure (NAHF).
From 2006 to 2011, 310 patients underwent CRT at Kobe University Hospital and Himeji Cardiovascular Center because of heart failure. Of these, 29 NAHF patients were retrospectively analyzed. The control group comprised 21 age- and ejection fraction-matched patients with NAHF who did not undergo CRT from the ICU database of Kobe University Hospital. The primary endpoint was all-cause death and hospitalization for heart failure. Response was defined as a >15% reduction in left ventricular end-systolic volume (LVESV).
CRT was performed successfully without serious complications in all patients. Twenty-three patients (79%) were discharged 19±15 days after CRT implantation, while 6 (21%) died during their hospital stay due to progressive heart failure. Compared with the control group, patients in the CRT group showed significant improvements in the primary endpoint (log-rank p=0.04). Six patients (21%) were defined as responders and the Kaplan-Meier curve showed that responders experienced a better outcome than non-responders (log-rank p=0.029). LV dyssynchrony before implantation was significantly related to the occurrence of the primary endpoint (p=0.02).
CRT can be safely used in patients with NAHF and can improve long-term patient outcomes, especially in treatment responders.
我们回顾了心脏再同步治疗(CRT)对纽约心脏协会(NYHA)IV级非卧床心力衰竭(NAHF)患者的有效性和安全性。
2006年至2011年,310例因心力衰竭在神户大学医院和姬路心血管中心接受CRT治疗的患者。其中,对29例NAHF患者进行了回顾性分析。对照组包括21例年龄和射血分数匹配的NAHF患者,这些患者来自神户大学医院重症监护病房数据库,未接受CRT治疗。主要终点是全因死亡和因心力衰竭住院。反应定义为左心室收缩末期容积(LVESV)减少>15%。
所有患者CRT均成功实施,无严重并发症。23例(79%)患者在CRT植入后19±15天出院,6例(21%)患者因进行性心力衰竭在住院期间死亡。与对照组相比,CRT组患者的主要终点有显著改善(对数秩检验p=0.04)。6例(21%)患者被定义为反应者,Kaplan-Meier曲线显示反应者的结局优于无反应者(对数秩检验p=0.029)。植入前左心室不同步与主要终点的发生显著相关(p=0.02)。
CRT可安全用于NAHF患者,并可改善患者长期结局,尤其是治疗反应者。